Biotechs dive deeper into targeted cancer research, despite costs

Drugmakers have found the inherent challenges of clinical trials can be more pronounced with targeted cancer therapies, like AstraZeneca's Lynparza, which go after specific genes or proteins. Finding and enrolling patients can take longer, and the costs associated with screening may pose another hurdle for smaller biotechs.